Contact:
4008465777
-
About Us
News & Events
-
10-12
Tonghua Dongbao obtains the Pharmaceutical Product Registration Certificate for repaglinide tablets
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”) received the Pharmaceutical Product Registration Certificate for repaglinide tablets issued by the National ...
-
09-21
Tonghua Dongbao: Clinical trial application for insulin degludec injection approved
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of approval (No. 2022LP01532 and No. 2022LP01538) from the Center for Drug...
-
08-30
Tonghua Dongbao becomes the first Chinese manufacturer to have its clinical trial application for insulin degludec and liraglutide injection accepted
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of acceptance from the Center for Drug Evaluation (CDE) of the National Me...
-
08-10
Tonghua Dongbao opens an online flagship store, tapping into Internet healthcare
Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") has doubled down on retail this year. Since March 2022, it has opened stores on mainstream e-commerce platform...
-
06-09
Tonghua Dongbao: Marketing application for GLP-1RA liraglutide injection accepted
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter "Tonghua Dongbao" or "the Company") received the notification of acceptance from the National Medical Products Administration (NMPA) on ...
-
05-19
Tonghua Dongbao: First subject enrolled in phase I clinical trial of BC Combo in Germany
In April 2022, Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice of approval from the Federal Institute for Drugs and Medical Devices (BfArM) in Germany...